Multiparametric magnetic resonance imaging in prostate cancer: present and future

John Kurhanewicz[a,b], **Daniel Vigneron**[a], **Peter Carroll**[b], and **Fergus Coakley**[a,b]

[a] Department of Radiology, University of California, San Francisco, California, USA

[b] Department of Urology, University of California, San Francisco, California, USA

Abstract

Purpose of review—The purpose of this article is to review the current status of advanced MRI techniques based on anatomic, metabolic and physiologic properties of prostate cancer with a focus on their impact in managing prostate cancer patients.

Recent findings—Prostate cancer can be identified based on reduced T_2 signal intensity on MRI, increased choline and decreased citrate and polyamines on magnetic resonance spectroscopic imaging (MRSI), decreased diffusivity on diffusion tensor imaging (DTI), and increased uptake on dynamic contrast enhanced (DCE) imaging. All can be obtained within a 60-min 3T magnetic resonance exam. Each complementary method has inherent advantages and disadvantages: T_2 MRI has high sensitivity but poor specificity; magnetic resonance spectroscopic imaging has high specificity but poor sensitivity; diffusion tensor imaging has high spatial resolution, is the fastest, but sensitivity/specificity needs to be established; dynamic contrast enhanced imaging has high spatial resolution, but requires a gadolinium based contrast agent injection, and sensitivity/specificity needs to be established.

Summary—The best characterization of prostate cancer in individual patients will most likely result from a multiparametric (MRI/MRSI/DTI/DCE) exam using 3T magnetic resonance scanners but questions remain as to how to analyze and display this large amount of imaging data, and how to optimally combine the data for the most accurate assessment of prostate cancer. Histological correlations or clinical outcomes are required to determine sensitivity/specificity for each method and optimal combinations of these approaches.

Keywords

diffusion tensor imaging; dynamic contrast imaging; magnetic resonance imaging; magnetic resonance spectroscopic imaging; prostate cancer

Introduction

Development of MRI as a clinically useful technique for the assessment of prostate cancer has been a research focus since the mid-1980s [1–5]. Vigorous progress still continues in the still-young science of prostate MRI, and in new, related imaging techniques such as magnetic resonance spectroscopic imaging (MRSI) [6], diffusion tensor imaging (DTI) [7,8], and dynamic contrast enhanced (DCE) imaging [9–15]. A number of recent MRI studies have demonstrated that the detection and characterization of prostate cancer can be improved through the addition of MRSI [16,17,18[•],19,20[•],21,22[•],23–26,27[••],28–30,31[•],32], DTI [33–38],

Correspondence to Dr John Kurhanewicz, Byers Hall, Room 203E, 1700 4th St, San Francisco, CA 94158-2330, USA, Tel: +1 415 514 9711; fax: +1 415 514 4714; John.Kurhanewicz@radiology.ucsf.edu.

and DCE imaging to an MRI staging exam [39••,40,41••,42–44], and by performing the imaging exam at 3T [45–47]. In this article, the current clinical status of these advanced imaging techniques for the detection and characterization of prostate cancer will be concisely reviewed with an emphasis on the clinical utility of the resulting imaging information.

Combined MRI/magnetic resonance spectroscopic imaging

While MRI traces anatomy, MRSI is used to spatially detect deviations from normal biochemistry that occur in tumor tissue. Specifically, magnetic resonance (MR) anatomic images, especially high spatial resolution combined endorectal coil pelvic phased array MR images, provide an excellent depiction of prostatic anatomy with regions of healthy prostate tissue demonstrating higher signal intensity than prostate cancer (Fig. 1a, red arrows) [1–5]. MRSI provides a noninvasive method of detecting small molecular markers (choline-containing metabolites, polyamines and citrate) within the cytosol and extracellular spaces of the prostate and is performed in conjunction with high-resolution anatomic imaging (MRI) [6]. On MRSI spectra, the resonances for choline, creatine, polyamines and citrate occur at distinct frequencies (Fig. 1b). The areas under these signals are related to the concentration of the respective metabolites, and changes in these concentrations can be used to identify cancer with high specificity [48,49]. Specifically, in spectra taken from regions of prostate cancer (Fig. 1b, red box), citrate and polyamines are significantly reduced or absent, while choline is elevated relative to spectra taken from surrounding healthy peripheral zone tissue. The morphologic and biochemical causes of these metabolic changes are fairly well understood and have been discussed in a review article [6]. There is also a growing amount of published data indicating the metabolic information provided by MRSI combined with the anatomical information provided by MRI can significantly improve the clinical assessment of cancer location and volume within the prostate [48,49–53], extracapsular spread [54,55••], and cancer aggressiveness [56,57]. The presence of tens of thousands of whole-body 1.5T MRI scanners in hospitals worldwide and the availability of commercial MRI/MRSI packages will allow the routine clinical use of these techniques in the near future.

Multiparametric MRI at 3T

Although 1.5T prostate MRI/^{1}H MRSI is now commercially available and is becoming more widely used, the growing availability of 3T MR scanners offers the potential for significant improvements in both spatial and spectral resolution and in speed [46,58,59]. Imaging at 3T can also improve DTI and DCE imaging that can provide additional quantitative functional measures of the prostate at a higher spatial resolution than MRSI [44,46,47,60]. DCE MRI provides valuable information concerning prostate cancer microvascularity and angiogenesis [9–15]. DCE MRI is performed by injecting a small molecular weight MR contrast agent (gadolinium-DTPA) into the patient, and measuring the increase in signal intensity on fast T_1-weighted images of the prostate. The rate of enhancement in the images is reflective of the vascular volume and the permeability of the vessels, while the magnitude of enhancement reflects the extravascular/extracellular leakage space. Studies have demonstrated that DCE MRI can discriminate prostate cancer from surrounding healthy prostate tissues based on a higher and faster rate of contrast enhancement (Fig. 1d) [15,61–64]. Diffusion-weighted imaging is sensitive to the motion of water molecules at microscopic spatial scales within biological tissues [7,8]. Unlike other tumors that demonstrate increased average water diffusivity ($<D>$) compared to surrounding benign tissues, initial studies suggest that prostate cancers demonstrate lower $<D>$ values (Fig. 1c) [34,36,65–69].

Detection and localization of cancer within the prostate

In clinical practice, reliable detection and localization of often small regions of prostate cancer is of increasing therapeutic importance due to the emergence of 'active surveillance' and focal

ablative therapy such as interstitial brachytherapy, intensity-modulated radiotherapy, high-intensity focused ultrasound, and cryosurgery [70]. MRI alone has demonstrated good sensitivity but poor specificity in detecting cancer in the prostate [44,71,72•]. Recent estimates using T_2-weighted sequences and endorectal coils vary from 60 to 96% [42]. The poor specificity is due to other benign pathologies [inflammation, stromal benign prostatic hyperplasia (BPH)] and therapy also causing a loss of ductal morphology and low T_2 on MRI [73•]. Additionally, infiltrating prostate cancer may not cause a reduction in normal glandular morphology and therefore will not be hypointense on MRI [73•]. Similar to imaging at 1.5T, T_2-weighted image quality, prostate cancer localization and staging is significantly improved at 3T with the use of an endorectal coil as compared with a external phased array coil [74•]. Identifying prostate cancer within the central gland is particularly difficult for MRI due to the overlap of T_2 weighted signal intensity in predominately stromal BPH. In a recent study of 148 prostate cancer patients prior to radical prostatectomy MRI alone detected transition zone prostate cancers with modest accuracy with areas under the reader operator curve (AUC) ranging from 0.73–0.75 [75].

The higher specificity of MRSI to metabolically identify cancer can be used to improve the ability of MRI to identify the location and volume of cancer within the prostate [48–50,76–78]. A study of 53 biopsy proven prostate cancer patients prior to radical prostatectomy and step-section pathologic examination demonstrated a significant improvement in cancer localization to a prostatic sextant (left and right; base, midgland, and apex) using combined MRI/MRSI versus MRI alone [49]. A combined positive result from both MRI and MRSI indicated the presence of tumor with high specificity (91%) while high sensitivity (95%) was attained when either test alone indicated the presence of cancer [49]. The addition of a positive sextant biopsy findings to concordant MRI/MRSI findings further increased the specificity (98%) of cancer localization [48]. More recent studies in early stage prostate cancer patients, however, have indicated that combined 1.5T MRI/MRSI does poorly at detecting and localizing small (<0.5 cm^3) low grade ($\leq 3 + 3$) tumors [57,76,78]. One study [57] demonstrated that overall sensitivity ofMR spectroscopic imaging was 56% for tumor detection, increasing from 44% in lesions with Gleason score of $3 + 3$ to 89% in lesions with Gleason score greater than or equal to $4 + 4$. The inability to detect small low grade tumors by 1.5T MRSI is primarily due to the partial voluming of surrounding benign tissue in spectroscopic volumes containing cancer due to the relatively coarse spatial resolution of 1.5T MRSI (0.34 cm^3, ~ 7 mm on a side). At 3T, higher spatial resolution of MRSI can be obtained (0.16 cm^3, ~ 5 mm on a side) in the same acquisition time as 1.5T, thereby improving the ability of MRSI to detect small, early stage tumors (Fig. 1b).

DTI and DCE images can be acquired at very high spatial resolution ($0.9 \times 1.8 \times 4$ mm) potentially improving MR detection of small low grade tumors, and within a matter of minutes allowing their addition to a clinically reasonable MRI/MRSI exam. DCE imaging at 1.5T and 3.0T demonstrated similar sensitivities (73 and 73%, respectively) and specificities (81 and 77%, respectively) for identifying cancer within the prostate [10,44]. In another study of 34 prostate cancer patients who received an MRI/MRSI/DCE exam prior to radical prostatectomy, it was demonstrated that reader accuracy in tumor detection was significantly (P <0.01) better for three-dimensional MRSI (AUC 0.80) and DCE (AUC 0.91) than T_2-weighted imaging (AUC 0.68) [41••]. No attempt was made, however, to determine the accuracy when all three techniques were combined. DTI studies at 3T also demonstrated good sensitivity (84%) and specificity (80%) for identifying cancer within the prostate [38], and the overall accuracy (AUC 0.89) was found to be better than that of T_2 imaging (AUC 0.82) [33]. A positive correlation was also found between MRSI and DTI findings for prostate cancer [68]. As demonstrated in Fig. 1, MRI/MRSI/DTI/DCE can be performed in a 1-h 3T MR exam; the most accurate detection and characterization of prostate cancer will most likely arise from combining information from all four techniques.

Tumor volume estimation

The pathologic finding that larger tumors are more likely to be of an advanced stage suggests measurement of prostate cancer tumor volume may provide important information on prognosis that is independent of direct morphologic assessment of extracapsular extension [79]. This has important implications for the potential prognostic role of imaging in prostate cancer, since 'it is beyond the capability of any current imaging study to detect microscopic local tumor extension' [80]. Two recent studies suggest that MRI/MRSI and DCE imaging may noninvasively provide estimates of cancer volume at diagnosis. One study [78] demonstrated that for nodules greater than 0.5 cm^3, tumor volume measurements by MRI, MRSI, and combined MRI and MRSI were all positively correlated with histopathologic volume (Pearson's correlation coefficients of 0.49, 0.59, and 0.55, respectively), but only measurements by MRSI and combined MRI/MRSI reached statistical significance ($P <0.05$). The addition of MRSI to MRI also increased the overall accuracy of prostate cancer tumor volume measurement, although measurement variability still limited consistent quantitative tumor volume estimation, particularly for small tumors (<0.5 cm^3). Another study [39$^{••}$] demonstrated that DCE imaging can determine the volume of smaller foci of prostate cancer with greater overall accuracy than MRI/MRSI. Sensitivity, specificity, and positive and negative predictive values for cancer detection by DCE imaging were 77%, 91%, 86% and 85% for foci greater than 0.2 cm^3, and 90%, 88%, 77% and 95% for foci greater than 0.5 cm^3, respectively.

Predicting organ confined prostate cancer

A more accurate prediction of organ confined prostate cancer at the time of diagnosis would allow the determination of whether 'focal therapy' is appropriate for a given patient. At 1.5T MRI, it has been demonstrated that anatomical features on MRI such as bulging of the prostate obliteration of the rectoprostatic angle and asymmetry of the neurovascular bundle can predict extra-capsular extension (ECE), with specificity up to 95% but with low sensitivity (38%) [81]. It was found that tumor volume per lobe estimated by MRSI was significantly ($P <0.01$) higher in patients with ECE than in patients without ECE [54]. Moreover the addition of an MRSI estimate of tumor volume to high specificity MRI findings for ECE [81] improved the diagnostic accuracy and decreased the inter-observer variability of MRI in the diagnosis of extracapsular extension of prostate cancer [54].

An important advance in the staging of prostate cancer has been the development of multivariable risk prediction instruments such as the Partin tables [82] and nomograms, which combine clinical stage, serum prostate specific antigen (PSA) levels, and grade of biopsies results to predict the pathologic stage of the cancer and likelihood of recurrence after therapy, respectively [83–85]. Two recent studies demonstrated that addition of MRI/MRSI findings could significantly improve the predictive ability of biopsy based staging nomograms. In a study of 24 prostate cancer patients prior to radical prostatectomy the addition of endorectal MRI results contributed significant incremental value to a nomogram for predicting seminal vesicle invasion (SVI). It was found that the nomogram plus endorectal MRI (0.87) had a significantly larger ($P <0.05$) AUC than either endorectal MRI alone (0.76) or the nomogram alone (0.80) [31$^{•}$]. In another study of 383 prostate cancer patients prior to radical prostatectomy, 1.5T MRI/MRSI data were added to a nomogram for predicting organ-confined prostate cancer (no ECE or SVI) in order to assess its incremental value. The contribution of MRI/MRSI findings were significant in all patient risk groups but were greatest in the intermediate- and high-risk groups ($P <0.01$ for both) [55$^{••}$].

Predicting indolent disease

Due to increased screening using serum PSA and extended-template transrectal ultrasound-guided biopsies, thousands of patients with prostate cancer are being identified at an earlier and potentially more treatable stage [86[••]]. The risk of overdetection, detecting a cancer which would not become clinically significant during that patient's lifetime if left untreated, however, has been estimated to vary between 15 and 84% [87–89]. Therefore there is an increased interest in active surveillance, but clinical parameters alone are not sufficient to predict a benign disease course. A recent study suggested that the addition of MRI/MRSI data to clinical parameters could improve this prediction. In a study of 220 patients prior to surgery, the addition of MRI (AUC 0.803) and MRI/MRSI (AUC 0.854) to biopsy based nomograms (basic AUC 0.57, comprehensive 0.73) was found to significantly improve the prediction of indolent prostate cancer using a surgical definition of indolent disease (no ECE or SVI and <0.5 cm^3 of cancer with no pattern 4 or 5 cancer) as the standard of reference [86[••]]. In another study of men who selected active surveillance, serial PSA levels were found to correlate with cancer but not BPH at serial endorectal MRI/MRSI, suggesting that PSA is a useful longitudinal tumor marker in this population [18[•]]. This study suggests that using a PSA velocity of over 0.75 ng/ml/year would allow the identification of men with progressive disease who would benefit from a follow-up imaging exam.

Conclusion

Commercial MRI/MRSI packages for staging prostate cancer on 1.5T MR scanners are now available and the technology is becoming mature enough to begin assessing its clinical utility in large patient cohort studies using surgical pathology or clinical outcomes as the standard of reference. Recent studies have demonstrated that 1.5T MRI/MRSI has the potential to significantly improve the local evaluation of prostate cancer presence and volume and has been shown to have a significant incremental benefit in the prediction of pathological stage when added to nomograms incorporating nonimaging preoperative risk factors. Combined 1.5T MRI/MRSI also has recognized limitations, including the potential for false positive and false negative results, particularly for small volume (<0.5 cm^3) early stage cancer. Recent studies have shown that accuracy can be improved by performing MRI/MRSI at higher magnetic field strengths (3T) and through the addition of other functional MR techniques, namely DTI and DCE imaging. There are currently no commercially available 3T MRI/MRSI/DTI/DCE staging exams but the ability to accomplish this exam on clinical 3T scanners in a clinical reasonable time has been demonstrated and commercial products should be available within the next couple of years. A challenge to the clinical utility of such a multiparametric exam is having the appropriate tools to analyze and display the large amount of data acquired and how to optimally combine the data to give the most accurate assessment of prostate cancer in individual patients.

Acknowledgments

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

• of special interest

•• of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 126–127).

1. Phillips ME, Kressel HY, Spritzer CE, et al. Prostatic disorders: MR imaging at 1.5 T. Radiology 1987;164:386–392. [PubMed: 2440074]

2. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal–pelvic phased-array coils. Radiology 1994;193:703–709. [PubMed: 7972810]

3. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987;162:331–336. [PubMed: 3797645]

4. Carrol CL, Sommer FG, McNeal JE, Stamey TA. The abnormal prostate: MR imaging at 1.5 T with histopathologic correlation. Radiology 1987;163:521–525. [PubMed: 2436253]

5. Bezzi M, Kressel HY, Allen KS, et al. Prostatic carcinoma: staging with MR imaging at 1.5 T. Radiology 1988;169:339–346. [PubMed: 3174982]

6. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451–463. [PubMed: 12353259]

7. Sinha S, Sinha U. In vivo diffusion tensor imaging of the human prostate. Magn Reson Med 2004;52:530–537. [PubMed: 15334571]

8. Neeman M, Dafni H. Structural, functional, and molecular MR imaging of the microvasculature. Annu Rev Biomed Eng 2003;5:29–56. [PubMed: 14527310]

9. Liney GP, Turnbull LW, Knowles AJ. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 1999;12:39–44. [PubMed: 10195328]

10. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997;203:645–652. [PubMed: 9169683]

11. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 1996;166:845–852. [PubMed: 8610561]

12. Barentsz JO, Engelbrecht M, Jager GJ, et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 1999;10:295–304. [PubMed: 10508289]

13. Namimoto T, Morishita S, Saitoh R, et al. The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. Comput Med Imaging Graph 1998;22:239–245. [PubMed: 9740041]

14. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99–109. [PubMed: 10657154]

15. Padhani AR, Hayes C, Landau S, Leach MO. Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 2002;15:143–153. [PubMed: 11870910]

16. Carroll PR, Coakley FV, Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol 2006;8 (Suppl 1):S4–S10. [PubMed: 17021625]

17. Casciani E, Gualdi GF. Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging. 2006 Sep 12; [Epub ahead of print].

18•. Coakley FV, Chen I, Qayyum A, et al. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int 2007;99:41–45. This paper demonstrates how PSA could be used to identify men with progressive disease on active surveillance that would benefit from a MRI/MRSI exam. [PubMed: 17227490]

19. Costouros NG, Coakley FV, Westphalen AC, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2007;188:812–816. [PubMed: 17312072]

20•. Futterer JJ, Engelbrecht MR, Jager GJ, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007;17:1055–

1065. This paper demonstrates that an endorectal coil is important for the most accurate staging of prostate cancer by MRI even at 3T. [PubMed: 17024497]

21. Girouin N, Mege-Lechevallier F, Tonina Senes A, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007;17:1498–1509. [PubMed: 17131126]

22•. Hom JJ, Coakley FV, Simko JP, et al. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features: initial experience. Radiology 2007;242:483–489. This paper indicates that the metabolic signature for HGPIN is between that of cancer and healthy and is not a confounding factor for the metabolic identification of cancer. [PubMed: 17179396]

23. Kwock L, Smith JK, Castillo M, et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol 2006;7:859–868. [PubMed: 17012048]

24. Manenti G, Squillaci E, Carlani M, et al. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiol Med (Torino) 2006;111:22–32. [PubMed: 16623302]

25. Mueller-Lisse UG, Swanson MG, Vigneron DB, Kurhanewicz J. Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score. Eur Radiol 2007;17:371–378. [PubMed: 16791635]

26. Pels P, Ozturk-Isik E, Swanson MG, et al. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed 2006;19:188–197. [PubMed: 16411280]

27• •. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007;99:786–793. This is a large presurgical patient cohort study that demonstrated the utility of adding MRI/MRSI findings to a biopsy-based nomogram for improved prediction of insignificant disease. This is a very important paper from the standpoint of selecting active surveillance patients. Similar studies need to be performed to determine the incremental value of performing the MR I/MRSI exam at 3T and adding DTI and DCE data to the exam. [PubMed: 17223922]

28. Taouli B. MR spectroscopic imaging for evaluation of prostate cancer. J Radiol 2006;87 (2 Pt 2):222–227. [PubMed: 16484947]

29. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007;244:797–806. [PubMed: 17652190]

30. van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006;65:291–303. [PubMed: 16618584]

31•. Wang L, Hricak H, Kattan MW, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007;242:182–188. This presurgical patient cohort study demonstrated the utility of adding MRI/MRSI findings to a biopsy-based nomogram for improved prediction of SVI. [PubMed: 17090712]

32. Wang L, Zhang J, Schwartz LH, et al. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol 2007;188:99–104. [PubMed: 17179351]

33. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007;61:297–302. [PubMed: 17085002]

34. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 2006;23:130–134. [PubMed: 16374882]

35. Mulkern RV, Barnes AS, Haker SJ, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006;24:563–568. [PubMed: 16735177]

36. Manenti G, Squillaci E, Di Roma M, et al. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging. Radiol Med (Torino) 2006;111:1124–1133. [PubMed: 17171522]

37. Hacklander T, Scharwachter C, Golz R, Mertens H. Value of diffusion-weighted imaging for diagnosing vertebral metastases due to prostate cancer in comparison to other primary tumors. Rofo 2006;178:416–424. [PubMed: 16612731]

38. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol 2006;41:185–188. [PubMed: 16428991]

39• •. Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176(6 Pt 1):2432–2437. This study demonstrated the ability of DCE MRI at 3T to estimate intraglandular tumor volume with pathologic correlation. [PubMed: 17085122]

40. Dafni, H.; Kim, S.; Panda, K., et al. Signal loss in DCE-MRI associated with tumor progression in prostate cancer bone metastasis model [abstract]. Proceedings of the 14th Scientific Meeting of the Society of Magnetic Resonance in Medicine; 6–12 May 2006; Seattle. Berkeley: ISMRM; 2006. Abstract 118

41• •. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449–458. This determines the accuracies of T2-weighted MR imaging, dynamic contrast material-enhanced MR imaging, and quantitative three-dimensional (3D) proton MR spectroscopic imaging using whole-mount histopathologic section findings as the reference standard. [PubMed: 16966484]

42. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50:1163–1174. [PubMed: 16842903]

43. Prando A. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. Int Braz J Urol 2006;32:727–728.

44. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. Journal of Computer Assisted Tomography 2006;30:7–11. [PubMed: 16365565]

45. Cunningham CH, Vigneron DB, Chen AP, et al. Design of flyback echo-planar readout gradients for MR spectroscopic imaging. Magn Reson Med 2005;54:1286–1289. [PubMed: 16187273]

46. Scheenen TW, Gambarota G, Weiland E, et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005;53:1268–1274. [PubMed: 15906304]

47. Chen AP, Cunningham CH, Ozturk-Isik E, et al. High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging 2007;25:1288–1292. [PubMed: 17520729]

48. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology [see comments]. J Urol 2000;164:400–404. [PubMed: 10893595]

49. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer. Localization with three-dimensional proton MR spectroscopic imaging: clinicopathologic study. Radiology 1999;213:473–480. [PubMed: 10551229]

50. Hasumi M, Suzuki K, Taketomi A, et al. The combination of multivoxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res 2003;23 (5b):4223–4227. [PubMed: 14666629]

51. Portalez D, Malavaud B, Herigault G, et al. Predicting prostate cancer with dynamic endorectal coil MR and proton spectroscopic MR imaging. J Radiol 2004;85 (12 Pt 1):1999–2004. [PubMed: 15692410]

52. Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res 2005;24:523–530. [PubMed: 16471314]

53. Vilanova JC, Barcelo J. Prostate cancer detection: MR spectroscopic imaging. Abdom Imaging 2007;32:253–261. [PubMed: 17476554]

54. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extra-capsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481–488. [PubMed: 10551230]

55• •. Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006;238:597–603. This large presurgical patient cohort study demonstrated the utility of adding MRI/MRSI findings to a biopsy-based nomogram for improved prediction of organ confined prostate cancer. This is a very important paper from the standpoint of selecting patients that are appropriate candidates for focal therapy. Similar studies need to be performed to determine the incremental value of performing the MR I/MRSI exam at 3T and adding DTI and DCE data to the exam. [PubMed: 16344335]

56. Kurhanewicz J, Vigneron DB, Males RG, et al. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115–138. viii–ix. [PubMed: 10664669]

57. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804–814. [PubMed: 15734935]

58. Chen AP, Cunningham CH, Kurhanewicz J, et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006;24:825–832. [PubMed: 16916699]

59. Cunningham CH, Vigneron DB, Marjanska M, et al. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005;53:1033–1039. [PubMed: 15844147]

60. Chen, AP.; Albers, M.; Kohler, SJ., et al. High-resolution hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T [abstract]. Proceedings of the 14th Scientific Meeting of the Society of Magnetic Resonance in Medicine; 6–12 May 2006; Seattle. Berkeley: ISMRM; 2006. p. 587

61. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med 2005;53:249–255. [PubMed: 15678552]

62. Jeukens CR, van den Berg CA, Donker R, et al. Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multislice CT. Phys Med Biol 2006;51:4329–4343. [PubMed: 16912384]

63. Hara N, Okuizumi M, Koike H, et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005;62:140–147. [PubMed: 15389803]

64. Schlemmer HP, Merkle J, Grobholz R, et al. Can preoperative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004;14:309–317. [PubMed: 14531000]

65. Choi YJ, Kim JK, Kim N, et al. Functional MR imaging of prostate cancer. Radiographics 2007;27:63–75. [PubMed: 17234999]

66. Katz S, Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am 2006;44:723–734. viii. [PubMed: 17030223]

67. Kozlowski P, Chang SD, Jones EC, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis: correlation with biopsy and histopathology. J Magn Reson Imaging 2006;24:108–113. [PubMed: 16767709]

68. Kumar V, Jagannathan NR, Kumar R, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006;24:541–548. [PubMed: 16735174]

69. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005;21:258–262. [PubMed: 15723379]

70. Carroll PR, Presti JJ, Small E, Roach MR. Focal therapy for prostate cancer 1996: maximizing outcome. Urology 1997;49 (suppl 3A):84–94. [PubMed: 9123742]

71. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal: pelvic phased-array coils. Radiology 1994;193:703–709. [PubMed: 7972810]

72•. Okamura T, Umemoto Y, Yamashita K, et al. Pitfalls with MRI evaluation of prostate cancer detection: comparison of findings with histopathological assessment of retropubic radical

prostatectomy specimens. Urol Int 2006;77:301–306. This good recent study looked at the accuracy of MRI for prostate cancer detection with pathologic correlation. [PubMed: 17135778]

73•. Hom JJ, Coakley FV, Simko JP, et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging–distinction of true-positive results from chance-detected lesions. Radiology 2006;238:192–199. This is an important paper from the stand-point of ensuring uniformity of scientific studies investigating the accuracy of MRSI for the detection of prostate cancer. [PubMed: 16373767]

74•. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T: comparison of image quality, localization, and staging performance. Radiology 2007;244:184–195. This is an important paper from the stand-point that it demonstrates the clinical benefits of using a endorectal coil at 3T. [PubMed: 17495178]

75. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006;239:784–792. This very large presurgical patient study demonstrated the accuracy of detecting central gland tumors using T_2 weighted imaging. [PubMed: 16569788]

76. Dhingsa R, Qayyum A, Coakley FV, et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004;230:215–220. [PubMed: 14695396]

77. Hasumi M, Suzuki K, Oya N, et al. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer. Anticancer Res 2002;22 (2B):1205–1208. [PubMed: 12168926]

78. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223:91–97. [PubMed: 11930052]

79. D'Amico AV, Chang H, Holupka E, et al. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 1997;49:385–391. [PubMed: 9123703]

80. Smith JA Jr, Scardino PT, Resnick MI, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multiinstitutional trial. J Urol 1997;157:902–906. [PubMed: 9072596]

81. Yu KK, Hricak H, Alagappan R, et al. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997;202:697–702. [PubMed: 9051019]

82. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110–114. [PubMed: 7685418]

83. Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007;177:107–112. [PubMed: 17162015]

84. Kattan MW, Eastham J. Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 2003;1:221–226. [PubMed: 15040880]

85. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–717. [PubMed: 16705126]

86• •. Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006;238:597–603. This is the first manuscript to demonstrate that the addition of MRI/MRSI data to a clinical nomogram significantly increases the accuracy of predicting indolent disease. [PubMed: 16344335]

87. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416–419. [PubMed: 11458039]

88. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–878. [PubMed: 12813170]

89. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981–990. [PubMed: 12096083]

Figure 1.
An example of a multiparametric 3T magnetic resonance exam of a 55-year-old patient with a prostate specific antigen of 8.46 ng/ml and biopsy-proven cancer (left apex, 1/12 cores having 5 mm of G3+3)

(a) T_2 weighted MRI showing a region of low signal intensity lesion (red arrows) in the right apex. (b) Corresponding spectral $0.16 cm^3$ array showing abnormal spectra (red box) in the same region as the suspicious region of low T_2 signal intensity. (c) A calculated water diffusion image demonstrating a reduction in intensity in the region of prostate cancer. (d) The contrast uptake curves from the region of prostate cancer (yellow) was more dramatic and washed-out faster than healthy prostate peripheral zone (green) tissue on dynamic contrast enhanced MRI. Prostate cancer in the left apex was confirmed at surgery.